Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes.

Objective: To assess metabolic outcomes in obese people with type 2 diabetes (T2D) in the first year following gastric bypass surgery.

Subjects And Methods: Forty-nine obese patients with T2D who had undergone gastric bypass surgery 12 or more months previously were identified. Body weight and glycosylated haemoglobin (HbA(1c)) pre-operatively and 3, 6 and 12 months postoperatively, changes to glucose-lowering therapies, and blood pressure (BP) and total and high-density lipoprotein (HDL) cholesterol pre-operatively and 12 months postoperatively were recorded.

The role of insulin detemir in overweight type 2 diabetes management.

The recent evidence-based shift towards an algorithm of early initiation and aggressive titration of insulin therapy in the management of type 2 diabetes requires the use of an effective insulin formulation that is both safe and acceptable to patients and physicians alike. The advent of the long-acting insulin analogues, insulin detemir and glargine, in the last decade has revolutionized insulin therapy in type 2 diabetes. Their unique pharmacokinetic and pharmacodynamic properties have offered tangible advantage over the conventional intermediate and long-acting insulin preparations in terms of improving glucose control as well as reducing risk of hypoglycemia and weight gain.

Tight glycaemic control and cardiovascular disease in type 2 diabetes.

The role of tight glycaemic control in reducing cardiovascular events and mortality in type 2 diabetes has not yet been firmly established. Recent clinical trials have yielded unexpected outcomes. This review summarizes the background and outcome of these trials and the implications for management of glycaemia in type 2 diabetes.

Recurrent spindle cell oncocytoma of the pituitary, a case report and review of literature.

Spindle cell oncocytoma (SCO) is a rare non-functioning tumour of the pituitary which has just been formally recognized as a distinct entity by the 2007 WHO classification of brain tumours. We report a case of SCO who presented with symptoms of visual blurring, weight loss, intermittent vomiting and excessive tiredness of several months duration. Investigations revealed a bitemporal visual field defect, a panhypopituitary hormonal profile and a large pituitary tumour with suprasellar extension.